{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:14:52Z","timestamp":1794003292708,"version":"4.8.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ijrobp.2026.04.002","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:07:08Z","timestamp":1780099628000},"page":"330-339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Results of a Phase 1 Open-Label, Dose-Escalation Study of Gene Therapy With AAV2-hAQP1 for Grade 2 and 3 Radiation-Induced Late Xerostomia and Parotid Gland Hypofunction"],"prefix":"10.1016","volume":"126","author":[{"given":"Michael T.","family":"Brennan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Passineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Sroussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dyani","family":"Gaudilliere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Zeldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2026.04.002_bib0001","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2026.04.002_bib0002","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.21.01208","article-title":"Salivary gland hypofunction and\/or xerostomia induced by nonsurgical cancer therapies: ISOO\/MASCC\/ASCO guideline","volume":"39","author":"Mercadante","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.002_bib0003","first-page":"1039","article-title":"A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life","volume":"18","author":"Jensen","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ijrobp.2026.04.002_bib0004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.radonc.2013.11.010","article-title":"Intensity-modulated radiation therapy for head and neck cancer: systematic review and meta-analysis","volume":"110","author":"Marta","year":"2014","journal-title":"Radiother Oncol."},{"key":"10.1016\/j.ijrobp.2026.04.002_bib0005","series-title":"Externally-Led Patient Focused Drug Development Meeting","article-title":"Xerostomia voice of the patient report","year":"2021"},{"key":"10.1016\/j.ijrobp.2026.04.002_bib0006","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/978-3-540-79885-9_20","article-title":"Aquaporin-1 gene transfer to correct radiation-induced salivary hypofunction","author":"Baum","year":"2009","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.ijrobp.2026.04.002_bib0007","doi-asserted-by":"crossref","first-page":"19403","DOI":"10.1073\/pnas.1210662109","article-title":"Early responses to adenoviral-mediated transfer of the aquaporin-1 cDNA for radiation-induced salivary hypofunction","volume":"109","author":"Baum","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ijrobp.2026.04.002_bib0008","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2026.04.002_bib0009","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ijrobp.2026.04.002_bib0010","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ijrobp.2026.04.002_bib0011","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/ana.26755","article-title":"Delandistrogene moxeparvovec gene therapy in ambulatory patients (aged \u22654 to <8 years) with Duchenne muscular dystrophy: 1-year interim results from study SRP-9001-103 (ENDEAVOR)","volume":"94","author":"Zaidman","year":"2023","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ijrobp.2026.04.002_bib0012","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2026.04.002_bib0013","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2026.04.002_bib0014","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2026.04.002_bib0015","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of lentiGlobin for sickle cell disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2026.04.002_bib0016","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.ymthe.2022.03.004","article-title":"Durability of transgene expression after rAAV gene therapy","volume":"30","author":"Muhuri","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.ijrobp.2026.04.002_bib0017","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.omtm.2020.10.006","article-title":"Transduction of salivary gland acinar cells with a novel AAV vector 44.9","volume":"19","author":"Di Pasquale","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ijrobp.2026.04.002_bib0018","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/gt.2010.128","article-title":"AAV2-mediated transfer of the human aquaporin-1 cDNA restores fluid secretion from irradiated miniature pig parotid glands","volume":"18","author":"Gao","year":"2011","journal-title":"Gene Ther"},{"key":"10.1016\/j.ijrobp.2026.04.002_bib0019","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0360-3016(01)01512-7","article-title":"Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer","volume":"50","author":"Eisbruch","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.04.002_bib0020","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/hed.20602","article-title":"Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module","volume":"29","author":"Rosenthal","year":"2007","journal-title":"Head Neck"},{"key":"10.1016\/j.ijrobp.2026.04.002_bib0021","series-title":"Anderson symptom inventory user guide, version 1","author":"Cleeland","year":"2009"},{"key":"10.1016\/j.ijrobp.2026.04.002_bib0022","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/thx.42.10.773","article-title":"A measure of quality of life for clinical trials in chronic lung disease","volume":"42","author":"Guyatt","year":"1987","journal-title":"Thorax"},{"key":"10.1016\/j.ijrobp.2026.04.002_bib0023","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ijrobp.2005.02.045","article-title":"Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report","volume":"63","author":"Jabbari","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.04.002_bib0024","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1006\/bbrc.1998.8395","article-title":"Acetylcholine acts on M3 muscarinic receptors and induces the translocation of aquaporin5 water channel via cytosolic Ca2+ elevation in rat parotid glands","volume":"245","author":"Ishikawa","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ijrobp.2026.04.002_bib0025","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3390\/cells9061547","article-title":"Insight into salivary gland aquaporins","volume":"9","author":"D'Agostino","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ijrobp.2026.04.002_bib0026","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.bbagen.2013.08.007","article-title":"Aquaporins in salivary glands and pancreas","volume":"1840","author":"Delporte","year":"2014","journal-title":"Biochim. Biophys Acta."},{"key":"10.1016\/j.ijrobp.2026.04.002_bib0027","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1006\/bbrc.1999.1828","article-title":"Involvement of vesicle-cytoskeleton interaction in AQP5 trafficking in AQP5-gene-transfected HSG cells","volume":"266","author":"Tada","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ijrobp.2026.04.002_bib28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1037\/h0073282","article-title":"Reflex secretion of the human parotid gland","volume":"1","author":"Lashley","year":"1916","journal-title":"J. exp. Psychol."}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162600564X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162600564X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:35:56Z","timestamp":1793604956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036030162600564X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S036030162600564X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.04.002","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of a Phase 1 Open-Label, Dose-Escalation Study of Gene Therapy With AAV2-hAQP1 for Grade 2 and 3 Radiation-Induced Late Xerostomia and Parotid Gland Hypofunction","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}